<DOC>
	<DOCNO>NCT00005021</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug , give drug different way , combine biological therapy chemotherapy may kill cancer cell . PURPOSE : Phase I trial study effectiveness topotecan , paclitaxel , carboplatin without filgrastim treat patient advance solid tumor lymphoma respond standard therapy .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Biological Therapy Treating Patients With Refractory Solid Tumor Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dos combine topotecan , paclitaxel , carboplatin ( TOPO/TAX/CBDCA ) without filgrastim ( G-CSF ) patient advance solid tumor lymphomas . II . Determine toxic effect regimen patient . III . Determine pharmacokinetics TOPO/TAX/CBDCA whether TAX/CBDCA affect pharmacokinetics TOPO day 1 compare TOPO administer alone day 3 . IV . Describe clinical response observe patient . OUTLINE : This dose escalation study combination topotecan/paclitaxel/carboplatin . Patients stratify accord prior chemotherapy radiotherapy ( yes v ) . Part I : Patients receive topotecan IV day 1-3 paclitaxel IV 3 hour carboplatin IV 30-60 minute , day 1 . Part II : Patients receive topotecan , paclitaxel , carboplatin part I , plus filgrastim ( G-CSF ) day 6-19 . Treatment repeat every 3 week absence disease progression unacceptable toxicity Cohorts 3-6 patient receive escalate dos topotecan/paclitaxel/carboplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : Approximately 20-30 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven advanced solid tumor lymphoma refractory standard therapy standard therapy exist drug use regimen constitute standard therapy Brain metastasis eligible provide : Evidence neurologic improvement normalization No evidence radiographic progression appropriate therapy Steroid dose stable ( give ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 0 1 Life expectancy : Greater 3 month Hematopoietic : Absolute granulocyte count least 2,000/mm2 Platelet count least 100,000/mm2 Hepatic : Bilirubin great 1.5 mg/dL Transaminases le 3 time normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No myocardial infarction within 6 month No history congestive heart failure No uncontrolled angina No uncontrolled arrhythmia Other : No concurrent medical illness active infection would render treatment unsafe Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior topotecan , paclitaxel , carboplatin allow progression observe great 3 month last dose No prior mitomycin nitrosoureas No 1 prior chemotherapy regimen At least 4 week since chemotherapy recover ( alopecia allow ) Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy 25 % bone marrow At least 4 week since radiotherapy recover ( alopecia allow ) Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>